Naturopathic Physician Argues Against Peptide Injections, Promotes Body's Natural Production via LCHPMF™ Framework
By
Dr. Jay Wrigley
Summary
A naturopathic physician with over 30 years of clinical experience critiques the current peptide trend (BPC-157, CJC-1295, semaglutide, etc.) and argues that instead of chasing injectable peptides, the body should be supported through the LCHPMF™ framework — providing raw materials so the body can produce its own peptides naturally. The article focuses on midlife health, hormone support, and metabolic function through a naturopathic lens.
Source
Key quotes
· 4 pulledIn my thirty-plus years of clinical practice as a naturopathic physician specializing in hormones and metabolism, I have watched countless trends rise and fall.
The current explosion of interest in peptides — BPC-157 for gut repair, CJC-1295 and ipamorelin for growth hormone support, semaglutide and tirzepatide analogs for appetite control, thymosin beta-4, and dozens of others — is one of the loudest I have seen.
I've found that the most powerful approach to midlife peptide support isn't an injection — it's the LCHPMF™ framework.
Why I focus on giving the body the raw materials it needs instead of chasing the latest injection.
You might also wanna read

The unregulated peptide boom: Americans risk unknown side effects for quick-fix weight loss and anti-aging drugs
Thousands of Americans are using unregulated peptides purchased online for weight loss, muscle growth, and anti-aging purposes, despite thes
Spotify
Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure
This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It cont
Derek Lowe on "Peptides"
Debunking the Scientific Foundation of Traditional Chinese Medicine
The article discusses a recent study claiming to reveal the scientific foundation of traditional Chinese medicine (TCM) by analyzing connect
https://doi.org/10.1126/science.aed8713
Comments
Sign in to join the conversation.
No comments yet. Be the first.
